Three Phase 3 Trials, Three Decisions to Measure Steroid-Toxicity Directly
Patients on long-term steroids for autoimmune and inflammatory diseases know the damage that these drugs cause. The question for sponsors has long been whether a trial can prove it. In June 2026, ...
Obexelimab Reduces Disease Flares and Steroid-Toxicity in IgG4-RD
An exciting Phase 3 trial has confirmed that obexelimab significantly reduces the risk of disease flare in IgG4-related disease (IgG4-RD) while also delivering measurable reductions in ...
Steroid-Sparing Is Not Enough: GCA Trials Need Toxicity Data
New phase 3 data from the GCAptAIN trial show that secukinumab enabled a shorter steroid taper, less exposure, and meaningfully lower steroid-toxicity in giant cell arteritis (GCA). Although the ...
Secukinumab Delivers Sustained Remission and Toxicity Reduction in PMR
For the majority of patients with polymyalgia rheumatica, glucocorticoids do not provide a durable solution. They induce remission, but they do not maintain it. REPLENISH, the largest PMR clinical ...
Six Months on Steroids: The Point at Which Toxicity Becomes Undeniable
A new prospective study published in Seminars in Arthritis and Rheumatism confirms what clinicians have long known but have been unable to quantify: steroid-toxicity is universal in patients on ...
Curious about the true cost of steroid-toxicity?
Download our infographic today
